Introduction to SPRINGBOARD®
The company has developed an insole which collect data in an app on a user's (diabetics) smartphone. Users will be able to track their progress and send their data to their selected Health Care Professionals (HCPs); such as gait metrics, balance, falls risk, significant change in activity, supported with analysed standardised questionnaires at frequent intervals. HCPs can better understand the user’s function outside of the clinic or acute setting and utilise the data to provide an optimised and personalised health care service.
Areas for sparring
For this SPRINGBOARD®, panelists with competencies/experience within these themes, are needed for sparring:
The company is at a strategic inflection point and is assessing alternatives to traditional venture capital funding. Current funding provides a runway until the end of 2025, with the potential to extend this through soft-finance mechanisms. To support long-term sustainability, the company aims to identify a viable path forward driven primarily by business development and revenue growth.
At present, the company generates limited sales to academic institutions, primarily universities using the insoles for research, testing, or clinical evaluation. While these sales validate the technology, they are insufficient to reach break-even or support scale. The company’s primary strategic focus is entry into the diabetic foot care pathway; however, this route is complex and slow to commercialise. There is therefore a need to assess the broader commercial landscape and evaluate complementary or alternative market opportunities that could accelerate revenue generation and reduce dependence on VC funding.
Industry: Welfare technology, Health Care, Health, rehabilitation
Development stage: Proof of concept
Company's CVR region: Capitol
Competencies in the panel:
- Business Development
- Financing, Funding & Raising Capital
- Sales
Note: This SPRINGBOARD® will be held in Danish.
The problem
Foot ulcers are one of the biggest hidden costs in global healthcare.
1 in 3 people with diabetes will develop an ulcer. 40% will recur within 12 months.
The solution
An insole measuring temperature and pressure monitoring to identify risk of ulcers.
Data is continuously tracked in real-time. Vibrations from the insoles can aid gait and balance.
USP
We offer therapeutic and preventative benefits In addition to clinically validated gait analysis.
Stakeholders
Clinician – prescribes the solution to the patient, remotely monitors the activity and risks.
Person with diabetes - uses the service where data is automatically relayed to the clinician continuously.
Payor – USD 10,000 saved for each diabetic foot ulcer avoided.
Clients and partner
Glostrup Hospital, NHS, Johns Hopkins Hospital, Imperial College London, among others.
Roadmap
2026
• Finalise production of 250 units
• Secure first commercial partner
• Enter the US market
2027
• Produce 1,000 units
• Secure three additional commercial partners
• Scale US market
• Supply to the NHS
• Enter the Middle East
2028
• Scale production to 10,000 units
• Expand across Europe
• Scale into the NHS
The Team
A – CEO background in human biology and design engineering. Responsible for partnerships, funding, company development.
B – CTO background in mechanical engineering and design engineering. Responsible for overall product development.
C – Finance, fractional background from Citi and private equity, MBA.
Traction
Patented, clinically proven, with regulatory approvals and strong partnerships.
